# Saya Bio

Saya Bio is a Private Equity based in San Francisco, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** San Francisco, United States
- **Region:** North America
- **Address:** San Francisco, CA, United States
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** saya.bio
- **LinkedIn:** https://www.linkedin.com/company/saya-bio

## Regulatory record

- **Reports private funds:** No

## About

SAYA BIO is a biopharmaceutical company founded in 2020 in Jalisco, Mexico. It focuses on expanding access to biological treatments within the healthcare sector. The company offers biological therapies and biosimilars to address regional healthcare needs.

## Sectors

- Healthcare Services
- Biotechnology

## Questions

### Who runs investment decisions at Saya Bio?

Saya Bio has not publicly disclosed the names of its founders, managing partners, or investment committee members. The website and available materials describe the team only in collective terms. No named individuals appear in SEC filings or press releases as of mid-2026.

### How does Saya Bio source its biologic drug candidates?

Saya states it sources through international partnerships — in-licensing biologic and biosimilar products from existing manufacturers and then funding the registration, marketing, and distribution efforts within Latin America. The firm does not disclose names of specific pharma partners or licensing terms.

### Does Saya Bio invest in drug discovery or clinical trials?

No. Saya does not run its own laboratories or discover new molecules. It targets drugs that are already developed and approved in major markets, funding their regulatory pathway and market entry in Latin American countries where biologic access remains limited.

### What geographic markets does Saya Bio serve?

Saya positions itself as a Pan-American biopharmaceutical company, with explicit focus on Latin America. The website discusses Latin American healthcare infrastructure and patient populations in the region, without naming individual countries where it operates.

### Does Saya Bio have publicly disclosed portfolio companies?

No. As of mid-2026, Saya Bio has not named any portfolio companies, drug products, co-investors, or pharma partners in public materials. The pipeline is described in general terms — biologic and biosimilar therapies — without identifiable asset-level detail.

### Where does Saya Bio's capital come from?

The source of Saya Bio's capital has not been disclosed. The firm describes itself as an asset manager and refers to a fund structure, but it does not identify limited partners, anchor investors, family office backing, or any other capital origin.

## Related profiles

- [Saxum Energy Partners](https://altss.com/profile/saxum-energy-partners)
- [Sayacorp](https://altss.com/profile/sayacorp)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/saya-bio

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology